EBUS

Praxis Medical Announces FDA Clearance of the EndoCore EBUS-TBNA Biopsy Device

Retrieved on: 
Tuesday, October 17, 2023

Praxis Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the EndoCore EBUS-TBNA fine needle biopsy device.

Key Points: 
  • Praxis Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the EndoCore EBUS-TBNA fine needle biopsy device.
  • This procedure is performed by inserting a long, flexible fine needle through a bronchoscope for biopsy and pathological analysis.
  • The device is powered by a motor that rotates the needle during biopsy to facilitate cellular harvesting.
  • “We expect the EndoCore device will collect larger samples of tissue with higher cellularity which could translate to higher success rates for ancillary testing.

Introducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniques

Retrieved on: 
Friday, September 8, 2023

Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.

Key Points: 
  • Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.
  • The BioStar® is intended to be used for both Conventional TBNA (cTBNA) and endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) diagnostic techniques.
  • Streamlined Workflow: With a user-friendly interface and intuitive setup, the BioStar® TBNA Needle streamlines procedural workflow, saving valuable time in busy clinical settings.
  • The BioStar® TBNA Needle is now available for medical practitioners in Europe and the rest of the world except USA*, seeking to elevate their diagnostic capabilities.

Introducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniques

Retrieved on: 
Friday, September 8, 2023

Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.

Key Points: 
  • Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.
  • The BioStar® is intended to be used for both Conventional TBNA (cTBNA) and endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) diagnostic techniques.
  • Streamlined Workflow: With a user-friendly interface and intuitive setup, the BioStar® TBNA Needle streamlines procedural workflow, saving valuable time in busy clinical settings.
  • The BioStar® TBNA Needle is now available for medical practitioners in Europe and the rest of the world except USA*, seeking to elevate their diagnostic capabilities.

WAYCEN, the first medical AI company to win 4 CES 2023 innovation awards "Proved K-Medtech"

Retrieved on: 
Thursday, January 5, 2023

Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row

Key Points: 
  • Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row
    WAYCEN swept CES 2023 innovation awards with medical AI products, collaborated with the medical staff
    SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- The company specialized in AI Medtech, WAYCEN (CEO Kyungnam Kim) made splendid achievements of winning four CES innovation awards for the first time among medical AI companies ahead of 'CES 2023', the world's largest electronics exhibition, which will be held in Las Vegas, United States, in next January.
  • Winning two awards solely for the products utilizing the real-time image analysis technology is to highlight innovations in WAYCEN's medical AI solution lineup.
  • It speaks volumes within the medical industry that medical professionals and AI-specialized company jointly developed clinically useful products through technical verifications and accomplished such great performance.
  • Also, it is the AI medtech-specialized company that was selected as the "Country Representative Innovation Company 1000'" and "MEDTECH INNOVATOR APAC TOP 4".

Growing Prevalence of Respiratory Disorders Will Push Pulmonology Devices Market to Present Significant Growth During 2020-2030 - Future Market Insights, Inc.

Retrieved on: 
Wednesday, October 19, 2022

NEWARK, Del., Oct. 18, 2022 /PRNewswire/ -- The global pulmonology devices market is expected to grow at a steady rate over the forecast period. The market for pulmonology devices will demonstrate substantial growth in the upcoming years. Heightened prevalence of respiratory disorders like asthma, lung cancers, chronic obstructive pulmonary disorders (COPD), and cystic fibrosis fuel the pulmonology devices market to grow at a robust CAGR of about 10.7%during the projected period.

Key Points: 
  • Heightened prevalence of respiratory disorders like asthma, lung cancers, chronic obstructive pulmonary disorders (COPD), and cystic fibrosis fuel the pulmonology devices market to grow at a robust CAGR of about 10.7%during the projected period.
  • Additionally, favorable reimbursement enforced for outpatient procedures is a factor that will positively impact the prospect of the pulmonology devices market.
  • This coupled with heightened demand for such products in the country is driving the growth of the pulmonology devices market in the U.S.
  • The U.K. and Japan are two other countries that are predicted to undergo notable growth in the pulmonology devices market during the forecast period.

Olympus Supports CMS Coverage Decision for Lung Cancer Screening

Retrieved on: 
Tuesday, May 24, 2022

CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.

Key Points: 
  • CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.
  • Earlier screening and detection may save the lives of those diagnosed with non-small cell lung cancer," said Paul Skodny, Executive Director of Global Health Economics and Market Access at Olympus Corporation of the Americas.
  • "Still, there is much work to be done to align CMS coverage through Medicare and Medicaid with lung cancer screening guidance so that the barriers to screening are eliminated."
  • Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Olympus Announces Release of Redesigned Guide Sheath Kit

Retrieved on: 
Wednesday, April 13, 2022

CENTER VALLEY, Pa., April 13, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced the release of its latest generation of Guide Sheath™ Kit, designed to facilitate access to lesions in peripheral regions of the lung via bronchoscopy with radial EBUS (endobronchial ultrasound).

Key Points: 
  • The Guide Sheath Kit 2 is used as part of Olympus' robust lung cancer portfolio that facilitates a physician's ability to precisely locate and sample lesions.
  • Called the Guide Sheath Kit 2, the new version of the device features a braided wire inside the guide sheath, providing kink resistance and greater flexibility1.
  • Guide Sheath Kit 2 is part of Olympus' larger lung cancer solutions for diagnosis and staging to help guide patient care.
  • Visit the Olympus website for more information about the Guide Sheath Kit 2 or visit the pulmonary product page for more information about Olympus's complete product line.

NJ Top Docs Has Reviewed & Approved Pulmonologist. Nader Mahmood, MD, FCCP of North Jersey Pulmonary Associates

Retrieved on: 
Friday, February 11, 2022

SCOTCH PLAINS, N.J., Feb. 11, 2022 /PRNewswire-PRWeb/ -- NJ Top Doc, Nader Mahmood, MD, FCCP is an experienced, highly skilled and respected pulmonary medicine specialist at North Jersey Pulmonary Associates.

Key Points: 
  • SCOTCH PLAINS, N.J., Feb. 11, 2022 /PRNewswire-PRWeb/ -- NJ Top Doc, Nader Mahmood, MD, FCCP is an experienced, highly skilled and respected pulmonary medicine specialist at North Jersey Pulmonary Associates.
  • Dr. Mahmood and his team at North Jersey Pulmonary Associates offer comprehensive care in the fields of lung and sleep disorders.
  • Prior to working at North Jersey Pulmonary Associates, Dr. Mahmood earned his undergraduate degree at Rutgers University and went on to earn his medical degree at St. George's University in Grenada, West Indies.
  • NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

Stephen Folger Grinton is recognized by Continental Who's Who

Retrieved on: 
Monday, January 17, 2022

LINCOLNTON, N.C., Jan. 17, 2022 /PRNewswire/ -- Stephen Folger Grinton is being recognized by Continental Who's Who as a Distinguished Pulmonologist and Sleep Medicine Specialist for his outstanding achievements in the medical field and his professional excellence at Atrium Health Pulmonology and Sleep Medicine - Lincoln.

Key Points: 
  • LINCOLNTON, N.C., Jan. 17, 2022 /PRNewswire/ -- Stephen Folger Grinton is being recognized by Continental Who's Who as a Distinguished Pulmonologist and Sleep Medicine Specialist for his outstanding achievements in the medical field and his professional excellence at Atrium Health Pulmonology and Sleep Medicine - Lincoln.
  • At Atrium Health Pulmonology and Sleep Medicine - Lincoln, located in Lincolnton, North Carolina, the highly-trained specialists are committed to providing the best possible care.
  • In addition to his current role, Dr. Grinton is a Clinical Associate Professor at the University of North Carolina.
  • A Fellow of the American College of Chest Physicians, Dr. Grinton is board-certified in Internal Medicine, Pulmonary Disease, and Sleep Medicine by the American Board of Internal Medicine.

Fifth Third Bank eBus Returns to the Road

Retrieved on: 
Wednesday, July 28, 2021

Fifth Third Bank today announced that its Financial Empowerment Mobile, commonly known as the eBus, is returning to the road after a COVID-19 pandemic hiatus.

Key Points: 
  • Fifth Third Bank today announced that its Financial Empowerment Mobile, commonly known as the eBus, is returning to the road after a COVID-19 pandemic hiatus.
  • (Photo: Business Wire)
    We could not be more excited about the return of our eBus to our local neighborhoods, said Stefanie Steward-Young, senior vice president and chief corporate social responsibility officer, Fifth Third Bank.
  • In addition to the ability to get vaccinated against COVID-19, residents will be able to board the Fifth Third Bank eBus for the following services:
    We are thrilled to have the Fifth Third eBus at our Dont Miss Your Shot!
  • Community members are greeted by Fifth Third Bank employee volunteers and community partner representatives at eBus events.